Home » Stocks » BWAY

Brainsway Ltd. (BWAY)

Stock Price: $8.92 USD -0.14 (-1.55%)
Updated Apr 19, 2021 3:36 PM EDT - Market open
Market Cap 145.56M
Revenue (ttm) 23.10M
Net Income (ttm) -10.33M
Shares Out 15.88M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $8.92
Previous Close $9.06
Change ($) -0.14
Change (%) -1.55%
Day's Open 8.97
Day's Range 8.74 - 9.34
Day's Volume 154,366
52-Week Range 5.52 - 11.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction

5 days ago - GlobeNewsWire

Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET

3 weeks ago - GlobeNewsWire

CRESSKILL, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today a...

1 month ago - GlobeNewsWire

CRESSKILL, N.J. and JERUSALEM, March 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain dis...

1 month ago - GlobeNewsWire

CRESSKILL, N.J. and JERUSALEM, March 01, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain diso...

1 month ago - GlobeNewsWire

CRESSKILL, N.J. and JERUSALEM, Feb. 22, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disor...

1 month ago - GlobeNewsWire

CRESSKILL, N.J. and JERUSALEM, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of b...

2 months ago - GlobeNewsWire

Following Historic Abraham Accords, Israel's Deep Transcranial Magnetic Stimulation (Deep TMS) Treatment to Come to the United Arab Emirates Following Historic Abraham Accords, Israel's Deep Transcrania...

2 months ago - GlobeNewsWire

FDA clearance for smoking cessation moves Brainsway towards a portfolio of neurological disorder treatments and extends the company's competitive advantage. The publication of positive real-world result...

3 months ago - Seeking Alpha

Brainsway Ltd. (BWAY) CEO Chris von Jako on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Monday, November 23, 2020, at 10:00 AM Eastern Time Monday, November 23, 2020, at 10:00 AM Eastern Time

5 months ago - GlobeNewsWire

CRESSKILL, N.J. and JERUSALEM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disor...

5 months ago - GlobeNewsWire

In conjunction with OCD Awareness Week, BrainsWay partners with mental health influencers and patients to increase education around misrepresentation of the disorder In conjunction with OCD Awareness We...

6 months ago - GlobeNewsWire

Deep TMS highlighted in 10 presentation posters at annual session Deep TMS highlighted in 10 presentation posters at annual session

6 months ago - GlobeNewsWire

CRESSKILL, N.J. and JERUSALEM, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of...

7 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Brainsway.

7 months ago - Zacks Investment Research

CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain d...

7 months ago - GlobeNewsWire

Brainsway (BWAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

Brainsway’s current valuation is low as a result of a decline in revenue due to COVID-19 lockdowns.s

7 months ago - Seeking Alpha

Brainsway (BWAY) news for Monday includes approval from the U.S. Food & Drug Administration (FDA) sending BWAY stock higher.

7 months ago - InvestorPlace

Company Intends to Execute a Controlled U.S. Market Release in Early 2021

7 months ago - GlobeNewsWire

BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of Brainsway (NASDAQ:BWAY) remained unaffected after the company reported Q2 results.

8 months ago - Benzinga

CRESSKILL, N.J. and JERUSALEM, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of ...

8 months ago - GlobeNewsWire

CRESSKILL, N.J. and JERUSALEM, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of b...

8 months ago - GlobeNewsWire

PATTERSON, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, toda...

8 months ago - GlobeNewsWire

BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q1 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

PATTERSON, N.J. and JERUSALEM, June 24, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, June 24th, by BrainsWay Ltd. (NASDAQ & TASE: BWAY), please note that, in the...

9 months ago - GlobeNewsWire

PATTERSON, N.J. and JERUSALEM, June 24, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain di...

9 months ago - GlobeNewsWire

New site features user-friendly layout, easy access to resources, and tools for those affected by COVID-19 New site features user-friendly layout, easy access to resources, and tools for those affected ...

10 months ago - GlobeNewsWire

PATTERSON, N.J., May 20, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today ...

10 months ago - GlobeNewsWire

Hadar Levy Promoted to Senior Vice President and General Manager of North America

11 months ago - GlobeNewsWire

BrainsWay will donate $1 per entry to the National Alliance of Mental Illness (NAMI) and each entry will be entered for a chance to win a $250 Amazon gift card BrainsWay will donate $1 per entry to the ...

11 months ago - GlobeNewsWire

PATTERSON, N.J., April 13, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, toda...

1 year ago - GlobeNewsWire

Brainsway Continues Growth Trajectory While Conserving Cash

1 year ago - Seeking Alpha

Brainsway Ltd. (BWAY) CEO Christopher von Jako on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Results demonstrate increased activity in attention-related brain networks treated with BrainsWay’s H6-coil, which correlate with observed improvement in ADHD symptoms

1 year ago - GlobeNewsWire

Lushi also to serve on Company’s audit committee Lushi also to serve on Company’s audit committee

1 year ago - GlobeNewsWire

Company to discontinue funding of study following insufficient demonstration of efficacy Company to discontinue funding of study following insufficient demonstration of efficacy

1 year ago - GlobeNewsWire

Shares of Brainsway are up 10% in premarket trading on positive trial results for its brain stimulation device as a smoking cessation tool for longtime chronic cigarette smokers.

1 year ago - Market Watch

Primary and secondary endpoint achieved with statistical significance

1 year ago - GlobeNewsWire

Brainsway Ltd. (BWAY) CEO David Zacut on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

JERUSALEM and HACKENSACK, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its subsidiary BrainsWay USA, Inc., a global leader in the advanced non-invasive treatment of...

1 year ago - GlobeNewsWire

JERUSALEM, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, announced today that it will be exhib...

1 year ago - GlobeNewsWire

Deep Transcranial Magnetic Stimulation (Deep TMS) helmet approved to treat MDD is now available in Greenwood Village Deep Transcranial Magnetic Stimulation (Deep TMS) helmet approved to treat MDD is now...

1 year ago - GlobeNewsWire

BrainsWay is a technology leader in the transcranial magnetic stimulation market which holds significant potential if it becomes widely accepted by doctors and patients.

1 year ago - Seeking Alpha

About BWAY

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains t... [Read more...]

Industry
Diagnostics & Research
IPO Date
Apr 17, 2019
Stock Exchange
NASDAQ
Ticker Symbol
BWAY
Full Company Profile

Financial Performance

In 2019, Brainsway's revenue was $23.10 million, an increase of 40.89% compared to the previous year's $16.40 million. Losses were -$10.33 million, 59.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Brainsway stock is "Strong Buy." The 12-month stock price forecast is 13.88, which is an increase of 55.61% from the latest price.

Price Target
$13.88
(55.61% upside)
Analyst Consensus: Strong Buy